Trade name : Bevatas
Active component : Bevacizumab
Strength availability : 400mg/16ml & 100mg/4ml
Manufactured by : intas
Package : 400mg of Bevacizumab containing vial
Category: Monoclonal antibody or Anti-angiogenesis drug Bevacizumab is sold under the brand name Bevatas which belongs to vascular endothelial growth factor directed antibody, the main ingredient which is used as bevacizumab. Bevatas consist of human framework regions and murine complimentarily-determining regions. Bevatas is a combined human monoclonal antibody IgG1, that predicament to and prohibits the biological activity of human vascular endothelial growth factor (VEGF)
Bevatas is indicated for the treatment
• In combination with 5-fluorouracil chemotherapy administered intravenously, first or second line drug of choice for Metastatic colon or rectal cancer
• Concurrent use with carboplatin and paclitaxel as first line therapy for Non-squamous, non-small cell lung cancer
• Used in the treatment of recurrent Glioblastoma in adults
• Concurrent use with interferon alfa for Metastatic renal cell cancer
• Concurrent use with paclitaxel & cisplatin or paclitaxel & topotecan for Metastatic cervical cancer
• In combination with paclitaxel, pegylated liposomal doxorubicin or topotecan for Epithelial ovarian, fallopian tube or peritoneal cancer.
MECHANISM OF ACTION
Bevatas constitute an active ingredient like Bevacizumab which joined to VEGF and will not have communication of VEGF to its receptors like Flt-1 & KDR that present on the surface of the cells. While this interaction inhibits endothelial cell proliferation and new blood vessel production occurs Hence in counts discontinuation of metastatic tumor cells growth happens.
Key point :
Avoid administrating Bevatas before at least 28 days following surgery and the wound is completely cured
Metastatic colorectal carcinoma :
The Bevatas usual dosage by concomitant with 5-fluorouracil based chemotherapy. Bevatas 5mg/kg for every 2 weeks IV in concomitant with bolus IFL Bevatas 10mg/kg for every 2 weeks IV in combination with FOLFOX4 Bevatas 5mg/kg IV for every 2 weeks or Bevatas 7.5 mg/kg as IV every 3 weeks by concurrently take with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapy
Non-small cell lung cancer :
The patients regular dosage of Bevatas is 15mg/kg IV for every 3 weeks by interacting with carboplatin and paclitaxel
Bevatas 10mg/kg administered IV for every 2 weeks
Metastatic renal cell cancer :
Concurrent use with interferon alfa.: The usual dose of Bevatas is 10mg/kg IV for every 2 weeks
Metastatic cervical cancer :
The usual dose of Bevatas; Bevatas 15mg/kg given intravenously for every 3 weeks by combining with paclitaxel and cisplatin or with paclitaxel and topotecan
Epithelial ovarian, fallopian tube or peritoneal cancer :
The usual dose of Bevatas for Platinum opposing:; 10mg/kg of Bevatas for every 2 weeks by concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan Or The regular dosage of Bevatas; 15mg/kg of Bevatas given through IV for every 3 weeks by combining with topotecan The usual dose of Bevatas for Platinum responsive; 15mg/kg given IV for 3 weeks in concomitant with carboplatin and paclitaxel for 6 to 8 cycles The recommended dosage of Bevatas; 15mg/kg of Bevatas given IV for 3 weeks by combining with gemcitabine & carboplatin for 6 to 10 cycles.
The pharmacokinetic form of Bevatas is assayed by measuring total serum Bevacizumab concentration.
The volume of distribution is 2.9 (22%) L
The terminal half life period of Bevacizumab is 20days (11 to 50days)
PREPARATION & ADMINISTRATION
Bevatas is intravenous solution At initial infusion: given IV infusion over 90 minutes Following infusions: give second infusion over 60 minutes, if tolerated Administer all following infusion over 30minutes Bevatas IV infusion is prepared in aseptic condition Bevatas 400mg containing 16ml solution whereas 100mg containing 4ml Bevatas dilute into 100ml of 0.9% NS Do not dilute with dextrose solution Dispose the remaining drug which is left in a vial under guidance of pharmacist.
If patient fail to take the dose or missed the cycle means must consult with oncologist and follow the regular dosing schedule Do not take overdose
Previously If you have taking or ever had DPD (dihydropyrimidine dehydrogenase) deficiency of enzyme . Inform the doctor about this then your doctor may preferably inform you avoid taking Bevatas. Discuss with the doctor that you have or have ever had renal, hepatic, or cardiac problem Discuss with the doctor that are you pregnant or plan to become pregnant. Avoid planning to have children while on treatment with Bevatas. You should use a essential method of conceiving to prevent pregnancy in yourself or your partner during your treatment with Bevatas. The drug will harm the fetus. Avoid breast feeding while on treatment with Bevatas While using Bevatas these are some other complications occurred during therapy, care should be taken Hypertension Posterior reversible encephalopathy syndrome Gastrointestinal perforations Wound healing complications Hemorrhage Arterial thromboembolic events Venous thromboembolic events Embryo fetal toxicity occurs
Pregnancy category: D while administrating Bevatas in pregnant women, positive evidence on fetal risk depends on human studies but potential benefits by using the drug may have common risk against fetus.
No contraindication occurred
Gastrointestinal perforation and fistulae
Surgery and wound healing complication
Arterial thromboembolic events
Venous thromboembolic events
Posterior reversible encephalopathy syndrome
Renal injury & Proteinuria
Congestive heart failure
Neutropenia, mucosal inflammation, infection, neuropathy, Epistaxis, erythrodysaesthesia.
Bevatas vial should be stored at 2 to 8℃ (36 to 46℉) Single use vial Discard the left out medicine under guidance of pharmacist